Sanofi has agreed to acquire Dren Bio's DR-0201, a first-in-class bispecific myeloid cell engager that induces deep B-cell depletion, for an upfront payment of $600 million.
IGM Biosciences has stopped the development of imvotamab and IGM-2644 after Phase 1b trials showed insufficient B cell depletion in rheumatoid arthritis and lupus patients.
BMO Capital has downgraded IGM Biosciences from Outperform to Market Perform, reducing the price target from $21 to $2, after the company announced the discontinuation of imvotamab and IGM-2644 in autoimmune diseases due to insufficient B cell depletion in Phase 1b studies.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.